Chiba Hiromu, Kambayashi Yumi, Ohuchi Kentaro, Amagai Ryo, Tamabuchi Erika, Hashimoto Akira, Fujimura Taku
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Case Rep Oncol. 2022 Feb 1;15(1):40-45. doi: 10.1159/000521843. eCollection 2022 Jan-Apr.
Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of cutaneous T-cell lymphomas (CTCLs). Since the objective response rate of bexarotene is relatively high, with no racial differences, bexarotene can be administered to patients with phototherapy-resistant early CTCL as one of the first-line therapies in real-world clinical practice. Although various adverse events caused by bexarotene have been reported, there have been no reports of drug eruptions caused by bexarotene. One of the possible reasons is that it is difficult to distinguish a drug eruption from recurrence of CTCL, histologically. In this report, drug eruptions in 2 patients with CTCL treated with bexarotene diagnosed by quantitative analysis of immunohistochemical staining by digital microscopy are described.
贝沙罗汀是一种第三代视黄酸X受体选择性维甲酸，已被批准用于治疗皮肤T细胞淋巴瘤（CTCL）。由于贝沙罗汀的客观缓解率相对较高，且无种族差异，在实际临床实践中，贝沙罗汀可作为一线治疗药物之一用于治疗对光疗耐药的早期CTCL患者。尽管已有报道贝沙罗汀会引起各种不良事件，但尚未有关于贝沙罗汀引起药疹的报道。可能的原因之一是，从组织学上很难将药疹与CTCL复发区分开来。在本报告中，描述了2例接受贝沙罗汀治疗的CTCL患者经数字显微镜免疫组织化学染色定量分析诊断出的药疹情况。
